Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

CBC-Backed Hasten Biopharmaceutical Announces Acquisition of 14 Celltrion Legacy…

According to the agreement, Hasten will own the Marketing Authorization Holder (MAH) rights for these 14 products in eight countries and regions, including South Korea*, Singapore, Thailand, Australia and China Hong Kong S.A.R. The deal not only enriches Hasten's product pipeline and supply chain system but also marks its business expansion across Pan-Asia region. As an innovative biopharmaceutical company focused on chronic diseases and critical care area, Hasten will expand its product…

ONWARD® Medical Obtains Debt Financing with up to €52.5 Million Secured Loan…

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)Runway Growth Capital LLC is a leading U.S.-based specialty finance lenderRelationship further strengthens Company's balance sheet ahead of pending FDA approval and expected Q4 launch of ARC-EX System in the U.S. EINDHOVEN, the Netherlands, June28, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company...

Information on the total number of voting rights and shares

REGULATED INFORMATIONInformation on the total number of voting rights and sharesMont-Saint-Guibert (Belgium), June 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,904,962.41 Total number of securities carrying voting rights: 34,373,015 (all ordinary...

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

thfloor, 75013 Paris, France.At the meeting, during which approximately 40% of shares were exercised, resolutions 1 through 28 were adopted and resolution 29 was rejected, consistent with the recommendations of the management.The detailed results of the vote and the resolutions are available on Cellectis' website: https://www.cellectis.com/en/investors/general-meetings/About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform...

Higher cantonal composition authority issues written court decision in respect…

Allschwil, Switzerland – June 28, 2024Idorsia Ltd (SIX: IDIA) today announced that it has received the written decision from the higher cantonal composition authority(obere kantonale Nachlassbehörde)(the Court) in respect to the approval of the amendments of the terms of its outstanding convertible bonds originally maturing on July 17, 2024 (ISIN: CH0426820350) decided at the bondholder meeting held on May 6, 2024.If no appeal is filed within the statutory period of 30 days, the...

Results of the Combined General Meeting of 28 June 2024

Lyon (France) and Cambridge (MA, US), 28 June 2024 - 5.45 pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections,announces the results of the shareholder vote following the Combined General Meeting held today, 28 June 2024, at the head office, located 60 avenue Rockefeller, 69008, Lyon.The shareholders approved all the resolutions on which the Board of Directors recommended a...

Pierre Fabre Laboratories announce granting of European marketing authorization…

The decision of the EC follows the favorable opinion issued on April 25 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). It is based on the results of two pivotal, multicenter, double-blind, randomized phase 3 studies in adults with overactive bladder symptoms. Study RVT-901-3003 (EMPOWUR) evaluated the efficacy, tolerability, and safety of vibegron (at a dose of 75 mg per day) over 12 weeks compared to placebo and with tolterodine as a…

Zealand Pharma major shareholder announcement: Van Herk Investments

Company announcement – No. 38 / 2024 Zealand Pharma major shareholder announcement: Van Herk InvestmentsCopenhagen, Denmark, 28 June 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 28 June 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:As...

Total number of shares and voting rights in Zealand Pharma at June 28, 2024

Company announcement – No. 37 / 2024 Total number of shares and voting rights in Zealand Pharma at June 28, 2024 Copenhagen, Denmark, June 28, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of...

Tiziana Receives $3.4 Million in Non-Dilutive Funding

here. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences commented, “Tiziana is pleased to receive $3.4 million in non-dilutive funding to support our ongoing Phase 2 trial of intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS) as well as our work in Alzheimer's Disease. We continue to explore all avenues to pursue further non-dilutive funding in the near term.” About Foralumab Activated T cells play an important role in the...

CO2 AI Launches First Solution to Compute Product Emissions at Scale

Traditional methods like manual Life Cycle Assessments (LCAs) are slow, inconsistent, and costly. According to the 2023 Carbon Survey by CO2 AI and Boston Consulting Group (BCG), only 38% of companies receive adequate product-level data from suppliers. Traditional methods like manual Life Cycle Assessments (LCAs) are slow, inconsistent, and costly. According to the 2023 Carbon Survey by CO2 AI and Boston Consulting Group (BCG), only 38% of companies receive adequate product-level data from...

Veterinary Ultrasound Market to Reach USD 539 Million by 2029: Trends, Drivers…

Browse in-depth TOC on "Veterinary Ultrasound Market" Browse in-depth TOC on "Veterinary Ultrasound Market" 230 - Tables 52 - Figures 250 - Pages Key Drivers and Challenges Factors propelling market growth include increasing pet ownership and healthcare spending, advancements in technology, growing awareness of animal health, and rising livestock populations. Challenges include the high cost of advanced devices, scarcity of skilled professionals, economic constraints in...

Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa

Bavarian Nordic is committed to support global efforts to address the mpox situation in Africa through a donation of 15,000 doses of mpox vaccineEmergency Use Authorization for the MVA-BN vaccine has been issued in the DR CongoCOPENHAGEN, Denmark, June 28, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced an extended commitment to help fight the current mpox outbreak in Africa. The Company's MVA-BN vaccine, the only FDA and EMA-approved mpox vaccine, which served as an important...

Roche's Vabysmo gets CHMP recommendation for third indication retinal vein…

Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to aflibercept If approved, Vabysmo would be the first and only bispecific antibody treatment available for the nearly one million people with RVO in the European UnionVabysmo is already approved in the US and Japan for RVO and in more than 95 countries around the world for people living with nAMD...

Endo Announces Commencement of OTCQX Trading

The OTCQX Market offers a valuable and convenient trading experience for U.S. investors, brokers and institutions. It is the premier market of OTC Markets Group, which is designed for established, investor-focused companies worldwide. Eligibility for trading on this platform requires companies to fulfill stringent financial and governance standards, adhere to U.S. securities laws, and maintain transparent and current disclosure. The OTCQX Market offers a valuable and convenient trading…

CHMP recommends EU approval of Roche's PiaSky for people with PNH, a rare…

If approved, PiaSky will be the first monthly subcutaneous (SC) treatment for paroxysmal nocturnal haemoglobinuria (PNH) in the EU Additionally, with the option to self-administer, PiaSky may provide an alternative to existing intravenous (IV) C5 inhibitors, potentially helping to reduce treatment burden 1 The recommendation is based on the COMMODORE 2 study results, where SC PiaSky given every month demonstrated equivalent disease control and comparable safety to IV eculizumab...

AB Science provides an update on the application for conditional marketing…

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSISParis, 28 June, 2024, 12:30pm CETAB Science SA(Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted, in line with the trend vote, a negative opinion on the application for conditional marketing authorization of...

SPINEART APPOINTS LAURENT NODÉ-LANGLOIS AS CHIEF TECHNOLOGY OFFICER TO LEAD…

Laurent joins Spineart with over 25 years of experience in biomechanics, surgical navigation, innovation and intellectual property. Prior to joining Spineart, he served as Managing Director at General Electric, playing a pivotal role in advancing GE Healthcare's 3D imaging and navigation technologies. Laurent joins Spineart with over 25 years of experience in biomechanics, surgical navigation, innovation and intellectual property. Prior to joining Spineart, he served as Managing Director at...

SciBase partner with a large health care group in Los Angeles, Unified Health…

"SciBase and Unified Health are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes," says Pia Renaudin, CEO of SciBase. "We are encouraged to see more patients getting access to our point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable." "SciBase and Unified Health are well aligned with a shared mission to provide clinicians…

XRP Healthcare: Helping to Transform HIV and AIDS Care with Innovative…

Valneva Receives Marketing Authorization in Europe for the World's First…

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by…

Addex Shareholders Approve All Resolutions at Annual General Meeting

Idorsia's JERAYGO (aprocitentan) approved in Europe as first and only ERA for…

CBC-Backed Hasten Biopharmaceutical Announces Acquisition of 14 Celltrion Legacy…

ONWARD® Medical Obtains Debt Financing with up to €52.5 Million Secured Loan…

Information on the total number of voting rights and shares

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Higher cantonal composition authority issues written court decision in respect…

Results of the Combined General Meeting of 28 June 2024

Pierre Fabre Laboratories announce granting of European marketing authorization…

Zealand Pharma major shareholder announcement: Van Herk Investments

Total number of shares and voting rights in Zealand Pharma at June 28, 2024

Tiziana Receives $3.4 Million in Non-Dilutive Funding

CO2 AI Launches First Solution to Compute Product Emissions at Scale

Veterinary Ultrasound Market to Reach USD 539 Million by 2029: Trends, Drivers…

Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa

Roche's Vabysmo gets CHMP recommendation for third indication retinal vein…

Endo Announces Commencement of OTCQX Trading

CHMP recommends EU approval of Roche's PiaSky for people with PNH, a rare…

AB Science provides an update on the application for conditional marketing…

SPINEART APPOINTS LAURENT NODÉ-LANGLOIS AS CHIEF TECHNOLOGY OFFICER TO LEAD…

SciBase partner with a large health care group in Los Angeles, Unified Health…